help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schuffenecker, I.
Right arrow Articles by Lenoir, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schuffenecker, I.
Right arrow Articles by Lenoir, G. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 2 487-491
Copyright © 1998 by The Endocrine Society

Original Studies

Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene1

Isabelle Schuffenecker2, Marie Virally-Monod, Richard Brohet, David Goldgar, Bernard Conte-Devolx, Laurence Leclerc, Olivier Chabre, Andree Boneu, Jean Caron, Chantal Houdent, Elisabeth Modigliani, Vincent Rohmer, Martin Schlumberger, Charis Eng3, Pierre Jean Guillausseau, Gilbert Marcel Lenoir and le groupe d’etude des tumeurs à calcitonine4

Laboratoire de Génétique, Hôpital Edouard Herriot, and CNRS UMR 5641, Université Claude Bernard (I.S., G.M.L.), Lyon, France; Service de Médecine Interne (M.V-M., P.J.G.), Hôpital Lariboisière, Paris, France; Unité d’Epidémiologie Génétique (R.B, D.G.), Centre International de Recherche sur le Cancer, Lyon, France; Service d’Endocrinologie (B.C.D), Centre Hospitalier Universitaire de Marseille, France; Service d’Endocrinologie (L.L.), Centre Hospitalier Universitaire de Lille, France; Service d’Endocrinologie (O.C.), Centre Hospitalier Universitaire de Grenoble, France; Service de Médecine Nucléaire (A.B.), Centre Claudius Régaud, Toulouse, France; Service de Médecine Interne (J.C.), Centre Hospitalier Universitaire de Reims, France; Service d’Endocrinologie (C.H.), Centre Hospitalier Universitaire de Rouen, France; Service d’Endocrinologie (E.M.), Hôpital Avicenne, Bobigny, France; Service de Médecine Interne (V.R.), Centre Hospitalier Universitaire d’Angers, France; Service de Médecine Nucléaire (M.S.), Institut Gustave Roussy, Paris, France; and Department of Adult Oncology (C.E.), Human Cancer Genetics Unit, Dana-Farber Institute, Harvard Medical School, Boston, Massachusetts; Service d’Endocrinologie, Centre Hospitalier Universitaire de Marseille, Marseille, France

Address all correspondence and requests for reprints to: Gilbert M. Lenoir, CNRS UMR 5641, Université Cloude Bernard, 8 avenue Rockefeller, 69373, Lyon cedex 08, France.

Germline mutations of the RET proto-oncogene are responsible for multiple endocrine neoplasia type 2, including multiple endocrine type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma. The relationship between specific mutations and syndromic features has been established. In particular, the risk for pheochromocytoma and hyperparathyroidism (HPT) in MEN 2A patients is clearly associated with the presence of the RET mutation at a specific position, i.e. at codon 634. Also, a correlation between a specific mutation, C634R, and the development of HPT has been suggested but is still controversial. To further investigate the relationship between specific mutations of codon 634 and the development of HPT, we studied a population of 188 individuals, carrying mutations at codon 634, namely C634R (65 patients belonging to 10 families), C634Y (80 patients belonging to 11 families), or the less frequent codon 634 mutations [i.e. C634S, C634F, C634G, or C634W (43 patients belonging to 9 families)]. In this series of patients, we defined an overall HPT prevalence of 19.1% and found that this prevalence did not vary significantly, with respect to the nature of the mutation. However, irrespective of the particular mutation, the prevalence of HPT showed a high interfamilial variability. The statistical model that best fitted with the observed data was in favor of the heterogeneity of the risk for HPT, with 40% of the families showing an HPT risk of 34% and 60% of the families showing an HPT risk of 9%. In addition, our study clearly demonstrated that HPT could be an early component of the disease and provided the first estimate of age-specific and mutation-specific HPT penetrance in individuals with mutations of codon 634 of the RET proto-oncogene.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
I. N Milos, K. Frank-Raue, N. Wohllk, A. L. Maia, E. Pusiol, A. Patocs, M. Robledo, J. Biarnes, M. Barontini, T. P Links, et al.
Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation
Endocr. Relat. Cancer, December 1, 2008; 15(4): 1035 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Cranston, C. Carniti, S. Martin, P. Mondellini, Y. Hooks, J. Leyland, S. Hodgson, S. Clarke, M. Pierotti, B. A. J. Ponder, et al.
A Novel Activating Mutation in the RET Tyrosine Kinase Domain Mediates Neoplastic Transformation
Mol. Endocrinol., July 1, 2006; 20(7): 1633 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. B. Jackson, M. Guttenberg, H. Hedrick, and T. Moshang Jr
Multiple Endocrine Neoplasia Type 2A in a Kindred With C634Y Mutation
Pediatrics, September 1, 2005; 116(3): e468 - e471.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. J. Marx and W. F. Simonds
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Endocr. Rev., August 1, 2005; 26(5): 615 - 661.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Frank-Raue, S. Rondot, W. Hoeppner, P. Goretzki, F. Raue, and W. Meng
Coincidence of Multiple Endocrine Neoplasia Types 1 and 2: Mutations in the RET Protooncogene and MEN1 Tumor Suppressor Gene in a Family Presenting with Recurrent Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4063 - 4067.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Yart, M. Gstaiger, C. Wirbelauer, M. Pecnik, D. Anastasiou, D. Hess, and W. Krek
The HRPT2 Tumor Suppressor Gene Product Parafibromin Associates with Human PAF1 and RNA Polymerase II
Mol. Cell. Biol., June 15, 2005; 25(12): 5052 - 5060.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. F. Simonds, C. M. Robbins, S. K. Agarwal, G. N. Hendy, J. D. Carpten, and S. J. Marx
Familial Isolated Hyperparathyroidism Is Rarely Caused by Germline Mutation in HRPT2, the Gene for the Hyperparathyroidism-Jaw Tumor Syndrome
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
L. Yip, G. J. Cote, S. E. Shapiro, G. D. Ayers, C. E. Herzog, R. V. Sellin, S. I. Sherman, R. F. Gagel, J. E. Lee, and D. B. Evans
Multiple Endocrine Neoplasia Type 2: Evaluation of the Genotype-Phenotype Relationship
Arch Surg, April 1, 2003; 138(4): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I.-J. Kim, H. C. Kang, J.-H. Park, J.-L. Ku, J.-S. Lee, H.-J. Kwon, K.-A. Yoon, S. C. Heo, H.-Y. Yang, B. Y. Cho, et al.
RET Oligonucleotide Microarray for the Detection of RET Mutations in Multiple Endocrine Neoplasia Type 2 Syndromes
Clin. Cancer Res., February 1, 2002; 8(2): 457 - 463.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al.
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5658 - 5671.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Niccoli-Sire, A. Murat, V. Rohmer, S. Franc, G. Chabrier, L. Baldet, B. Maes, F. Savagner, S. Giraud, S. Bezieau, et al.
Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3746 - 3753.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Wiench, Z. Wygoda, E. Gubala, J. Wloch, K. Lisowska, J. Krassowski, D. Scieglinska, A. Fiszer-Kierzkowska, D. Lange, D. Kula, et al.
Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients
J. Clin. Oncol., March 1, 2001; 19(5): 1374 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. J. Marx
Hyperparathyroid and Hypoparathyroid Disorders
N. Engl. J. Med., December 21, 2000; 343(25): 1863 - 1875.
[Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J. R Hansford and L. M Mulligan
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
J. Med. Genet., November 1, 2000; 37(11): 817 - 827.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Marx
CLINICAL REVIEW 109: Contrasting Paradigms for Hereditary Hyperfunction of Endocrine Cells
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3001 - 3009.
[Full Text]

Home page
 JCOHome page
C. Eng
RET Proto-Oncogene in the Development of Human Cancer
J. Clin. Oncol., January 1, 1999; 17(1): 380 - 380.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society